Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies

Kuang-Yu Jen, Alan M. Gewirtz

Research output: Contribution to journalReview article

62 Citations (Scopus)

Abstract

At least three different approaches may be used for gene targeting including: A) gene knockout by homologous recombination; B) employment of synthetic oligonucleotides capable of hybridizing with DNA or RNA, and C) use of polyamides and other natural DNA-bonding molecules called lexitropsins. Targeting mRNA is attractive because mRNA is more accessible than the corresponding gene. Three basic strategies have emerged for this purpose, the most familiar being to introduce antisense nucleic acids into a cell in the hopes that they will form Watson-Crick base pairs with the targeted gene's mRNA. Duplexed mRNA cannot be translated, and almost certainly initiates processes which lead to its destruction. The antisense nucleic acid can take the form of RNA expressed from a vector which has been transfected into the cell, or take the form of a DNA or RNA oligonucleotide which can be introduced into cells through a variety of means. DNA and RNA oligonucleotides can be modified for stability as well as engineered to contain inherent cleaving activity. It has also been hypothesized that because RNA and DNA are very similar chemical compounds, DNA molecules with enzymatic activity could also be developed. This assumption proved correct and led to the development of a 'general-purpose' RNA-cleaving DNA enzyme. The attraction of DNAzymes over ribozymes is that they are very inexpensive to make and that because they are composed of DNA and not RNA, they are inherently more stable than ribozymes. Although mRNA targeting is impeccable in theory, many additional considerations must be taken into account in applying these strategies in living cells including mRNA site selection, drug delivery and intracellular localization of the antisense agent. Nevertheless, the ongoing revolution in cell and molecular biology, combined with advances in the emerging disciplines of genomics and informatics, has made the concept of nontoxic, cancer-specific therapies more viable then ever and continues to drive interest in this field.

Original languageEnglish (US)
Pages (from-to)307-319
Number of pages13
JournalStem Cells
Volume18
Issue number5
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Gene Expression
Messenger RNA
RNA
DNA
Oligonucleotides
Catalytic RNA
Nucleic Acids
Catalytic DNA
Gene Knockout Techniques
Informatics
Gene Targeting
Homologous Recombination
Nylons
Genomics
Base Pairing
Genes
Cell Biology
Molecular Biology
Enzymes
Pharmaceutical Preparations

Keywords

  • Antisense
  • DNA oligonucleotide
  • Gene targeting
  • Hairpin ribozymes
  • Hammerhead ribozymes
  • RNA
  • Targeted gene disruption

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

Suppression of gene expression by targeted disruption of messenger RNA : Available options and current strategies. / Jen, Kuang-Yu; Gewirtz, Alan M.

In: Stem Cells, Vol. 18, No. 5, 01.01.2000, p. 307-319.

Research output: Contribution to journalReview article

@article{efba86e563754f2ab7b0861ece094f72,
title = "Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies",
abstract = "At least three different approaches may be used for gene targeting including: A) gene knockout by homologous recombination; B) employment of synthetic oligonucleotides capable of hybridizing with DNA or RNA, and C) use of polyamides and other natural DNA-bonding molecules called lexitropsins. Targeting mRNA is attractive because mRNA is more accessible than the corresponding gene. Three basic strategies have emerged for this purpose, the most familiar being to introduce antisense nucleic acids into a cell in the hopes that they will form Watson-Crick base pairs with the targeted gene's mRNA. Duplexed mRNA cannot be translated, and almost certainly initiates processes which lead to its destruction. The antisense nucleic acid can take the form of RNA expressed from a vector which has been transfected into the cell, or take the form of a DNA or RNA oligonucleotide which can be introduced into cells through a variety of means. DNA and RNA oligonucleotides can be modified for stability as well as engineered to contain inherent cleaving activity. It has also been hypothesized that because RNA and DNA are very similar chemical compounds, DNA molecules with enzymatic activity could also be developed. This assumption proved correct and led to the development of a 'general-purpose' RNA-cleaving DNA enzyme. The attraction of DNAzymes over ribozymes is that they are very inexpensive to make and that because they are composed of DNA and not RNA, they are inherently more stable than ribozymes. Although mRNA targeting is impeccable in theory, many additional considerations must be taken into account in applying these strategies in living cells including mRNA site selection, drug delivery and intracellular localization of the antisense agent. Nevertheless, the ongoing revolution in cell and molecular biology, combined with advances in the emerging disciplines of genomics and informatics, has made the concept of nontoxic, cancer-specific therapies more viable then ever and continues to drive interest in this field.",
keywords = "Antisense, DNA oligonucleotide, Gene targeting, Hairpin ribozymes, Hammerhead ribozymes, RNA, Targeted gene disruption",
author = "Kuang-Yu Jen and Gewirtz, {Alan M.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1634/stemcells.18-5-307",
language = "English (US)",
volume = "18",
pages = "307--319",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Suppression of gene expression by targeted disruption of messenger RNA

T2 - Available options and current strategies

AU - Jen, Kuang-Yu

AU - Gewirtz, Alan M.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - At least three different approaches may be used for gene targeting including: A) gene knockout by homologous recombination; B) employment of synthetic oligonucleotides capable of hybridizing with DNA or RNA, and C) use of polyamides and other natural DNA-bonding molecules called lexitropsins. Targeting mRNA is attractive because mRNA is more accessible than the corresponding gene. Three basic strategies have emerged for this purpose, the most familiar being to introduce antisense nucleic acids into a cell in the hopes that they will form Watson-Crick base pairs with the targeted gene's mRNA. Duplexed mRNA cannot be translated, and almost certainly initiates processes which lead to its destruction. The antisense nucleic acid can take the form of RNA expressed from a vector which has been transfected into the cell, or take the form of a DNA or RNA oligonucleotide which can be introduced into cells through a variety of means. DNA and RNA oligonucleotides can be modified for stability as well as engineered to contain inherent cleaving activity. It has also been hypothesized that because RNA and DNA are very similar chemical compounds, DNA molecules with enzymatic activity could also be developed. This assumption proved correct and led to the development of a 'general-purpose' RNA-cleaving DNA enzyme. The attraction of DNAzymes over ribozymes is that they are very inexpensive to make and that because they are composed of DNA and not RNA, they are inherently more stable than ribozymes. Although mRNA targeting is impeccable in theory, many additional considerations must be taken into account in applying these strategies in living cells including mRNA site selection, drug delivery and intracellular localization of the antisense agent. Nevertheless, the ongoing revolution in cell and molecular biology, combined with advances in the emerging disciplines of genomics and informatics, has made the concept of nontoxic, cancer-specific therapies more viable then ever and continues to drive interest in this field.

AB - At least three different approaches may be used for gene targeting including: A) gene knockout by homologous recombination; B) employment of synthetic oligonucleotides capable of hybridizing with DNA or RNA, and C) use of polyamides and other natural DNA-bonding molecules called lexitropsins. Targeting mRNA is attractive because mRNA is more accessible than the corresponding gene. Three basic strategies have emerged for this purpose, the most familiar being to introduce antisense nucleic acids into a cell in the hopes that they will form Watson-Crick base pairs with the targeted gene's mRNA. Duplexed mRNA cannot be translated, and almost certainly initiates processes which lead to its destruction. The antisense nucleic acid can take the form of RNA expressed from a vector which has been transfected into the cell, or take the form of a DNA or RNA oligonucleotide which can be introduced into cells through a variety of means. DNA and RNA oligonucleotides can be modified for stability as well as engineered to contain inherent cleaving activity. It has also been hypothesized that because RNA and DNA are very similar chemical compounds, DNA molecules with enzymatic activity could also be developed. This assumption proved correct and led to the development of a 'general-purpose' RNA-cleaving DNA enzyme. The attraction of DNAzymes over ribozymes is that they are very inexpensive to make and that because they are composed of DNA and not RNA, they are inherently more stable than ribozymes. Although mRNA targeting is impeccable in theory, many additional considerations must be taken into account in applying these strategies in living cells including mRNA site selection, drug delivery and intracellular localization of the antisense agent. Nevertheless, the ongoing revolution in cell and molecular biology, combined with advances in the emerging disciplines of genomics and informatics, has made the concept of nontoxic, cancer-specific therapies more viable then ever and continues to drive interest in this field.

KW - Antisense

KW - DNA oligonucleotide

KW - Gene targeting

KW - Hairpin ribozymes

KW - Hammerhead ribozymes

KW - RNA

KW - Targeted gene disruption

UR - http://www.scopus.com/inward/record.url?scp=0033834587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033834587&partnerID=8YFLogxK

U2 - 10.1634/stemcells.18-5-307

DO - 10.1634/stemcells.18-5-307

M3 - Review article

C2 - 11007915

AN - SCOPUS:0033834587

VL - 18

SP - 307

EP - 319

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 5

ER -